Irish company Novus Diagnostics has been awarded €2.4 million in funding to commercialise its rapid sepsis test.
The only Irish company to be awarded funding from this round of the European Innovation Council (EIC) Accelerator pilot, DCU-based Novus Diagnostics has been working in collaboration with two Dublin hospitals on validating the SepTec diagnostic device.
The test aims to prevent millions of deaths each year from sepsis. According to data provided by the company, 49 million patients are diagnosed annually with sepsis and 11 million of them die; 80 per cent of these deaths could be prevented with rapid diagnosis and treatment.